跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

Y0001305

Cefpodoxime proxetil

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H27N5O9S2
CAS号:
分子量:
557.60
UNSPSC代码:
41116107
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

cefpodoxime

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

−20°C

SMILES字符串

[s]1c(nc(c1)\C(=N\OC)\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)OC(OC(=O)OC(C)C)C)COC)N

InChI

1S/C21H27N5O9S2/c1-9(2)33-21(30)35-10(3)34-19(29)15-11(6-31-4)7-36-18-14(17(28)26(15)18)24-16(27)13(25-32-5)12-8-37-20(22)23-12/h8-10,14,18H,6-7H2,1-5H3,(H2,22,23)(H,24,27)/b25-13-/t10?,14-,18-/m1/s1

InChI key

LTINZAODLRIQIX-FBXRGJNPSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Cefpodoxime proxetil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Vasu Kumar Kakumanu et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 128(3), 439-445 (2008-03-04)
Cefpodoxime proxetil (CP) is a prodrug with poor oral bioavailability because of its metabolism to Cefpodoxime acid (CA) in luminal contents and intestinal epithelial cells. In the present investigation, regional variability in different segments of the gastrointestinal tract vis-à-vis solubility
Vasu Kumar Kakumanu et al.
International journal of pharmaceutics, 317(2), 155-160 (2006-04-20)
Learning about the behavior of a drug in biological environment enables application of better formulation strategies to improve bioavailability of the same. Cefpodoxime proxetil (CP) is a prodrug, which is orally administered cephalosporin with only 50% absolute bioavailability. Despite previous
Momin A Mujeeb et al.
Indian journal of medical sciences, 65(2), 43-49 (2011-02-01)
Cefpodoxime is a semisynthetic third generation cephalosporin analogue with a relatively broader spectrum of antimicrobial activity against gram negative and gram positive organisms. This is attributed to their somewhat increased resistance to degradation by the betalactamase. Cefpodoxime shows good activity
Vasu Kumar Kakumanu et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 64(2), 255-259 (2006-06-27)
Cefpodoxime proxetil (CP) is a prodrug of cefpodoxime acid (CA), and is supplied as racemic mixture of R- and S-enantiomers. CP has only 50% absolute bioavailability, and the reasons responsible for low bioavailability remain poorly understood. The present work ascertains
Abhijit A Date et al.
International journal of pharmaceutics, 329(1-2), 166-172 (2006-10-03)
Self-nanoemulsifying drug delivery systems (SNEDDS) were developed with the objective to overcome problems associated with the delivery of cefpodoxime proxetil (CFP), a poorly bioavailable high dose antibiotic having pH dependant solubility. Solubility of CFP in oily phases and surfactants was

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门